Lung cancer
ME12 Meet the expert
Comorbidities in lung cancer progression
Clinical
Registration for this session is additional to the congress registration fee and is €122 on site, €110 standard.
Aims : The aim of this session is to demonstrate the importance of lung cancer comorbidities, including interstitial lung diseases, chronic obstructive pulmonary disease, and previous or other malignancies. How these various comorbidities affect lung cancer progression and how medications for these other illnesses impact the care of lung cancer patients will be examined.
Target audience :
Allied health professional, Anaesthesiologist, Clinician, Fellow, General practitioner, Junior member, Nurse, Oncologist, Pathologist, Pharmaceutical industry representative, Pulmonologist, Radiologist, Researcher, Resident, Respiratory physician, Scientist, Student, Thoracic endoscopist, Thoracic surgeon
13:00
Comorbidities in lung cancer progression
P. Schnabel(Homburg (Saar), Germany)
COI
N. Kahn(Heidelberg, Germany)
COI
1
4327
. . .
